Research

Learn about published research as well as leading-edge basic and translational research initiatives from St. Jude laboratories.

Blazing a TRAIL in acute myeloid leukemia treatment

Brian O'Flynn, PhD

See how studies into AML drug reveals new potential target

Study reveals the neurochemical gatekeeper to learning and the key to unlocking it

Brian O'Flynn, PhD

St. Jude research uncovers neural secrets behind our capacity to learn

Drug which blocks stress granule formation offers insight into biomolecular condensates

Brian O'Flynn, PhD

See how G3BP inhibitors represent turning point in RNP granule research

Jeffery Klco and Juan Barajas
Jeffery Klco and Juan Barajas

Following the breadcrumbs: Gain-of-function mutation leads researchers to new therapeutic target for pediatric AML

Brian O'Flynn, PhD

Explore the mechanistic insights behind novel pediatric AML therapeutic target

Graphic depicting infant vaccination
Graphic depicting infant vaccination

Exploring the interplay between vaccines and immune system development in infants

Brian O'Flynn, PhD

Explore new research delving into pediatric immune responses to vaccination

3 men in a lab
3 men in a lab

CRISPR kickstarts combination drug discovery for neuroblastoma

Alex Generous, PhD

A CRISPR screen reveals a potential combination therapy for relapsed neuroblastoma.

Finding the big-TIME players holding back CAR T–cell therapy for high-grade gliomas

Alex Generous, PhD

Explore how tumor-associated macrophages shape CAR T-cell therapy efficacy in high-grade gliomas.

(L to R) First author Prahalathan Pichavaram, PhD, corresponding author Andrew Murphy, MD, St. Jude Department of Surgery and co-author Carolyn Jablonowski, PhD.
(L to R) First author Prahalathan Pichavaram, PhD, corresponding author Andrew Murphy, MD, St. Jude Department of Surgery and co-author Carolyn Jablonowski, PhD.

Ribosome production presents a new therapeutic opportunity against Wilms tumor

Alex Generous, PhD

Discover how disruption ribosomes creation provides promise for “undruggable” cancers.

Ashraf Mohommed and Aseem Ansari
Ashraf Mohommed and Aseem Ansari

Just like the real thing: Synthetic gene expression regulators demonstrate success

Brian O'Flynn, PhD

See how Aseem Ansari's SynGRs target BET proteins, offering potential for treating diseases like Friedreich’s ataxia and advancing BET domain understanding

Clifford Brangwynne, PhD, Princeton University
Clifford Brangwynne, PhD, Princeton University

St. Jude Research Collaboratives program reaches across institutional boundaries to multiply impact

Jessica Gullett-Rubino, PhD

Learn more about how the St. Jude Research Collaboratives Program is driving scientific breakthroughs.